Temporal trends of outcomes of neutropenic patients with ARDS enrolled in therapeutic clinical trials

Price, David R.; Hoffman, Katherine L.; Sánchez, Elizabeth; Choi, Augustine M.K.; Siempos, Ilias I.

doi:10.1007/s00134-020-06263-4

Cited by 8 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondary outcomes were differences in ventilator-free days, ICU-free days and prevalence of rapidly improving AHRF between compared groups through day 28 following intubation. As previously 15,16 , ventilator-free days were defined as the number of days from the end of the last period of assisted breathing up to day 28. Hospitalized patients who died before day 28 were considered to have zero ventilator-free days.…”

Section: Discussionmentioning

confidence: 99%

Drug-overdose associated acute hypoxemic respiratory failure: A secondary analysis

Gkirgkiris,

Papoutsi,

Athanasiou

et al. 2024

Pneumon

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Drug-overdose associated acute hypoxemic respiratory failure: A secondary analysis

Gkirgkiris,

Papoutsi,

Athanasiou

et al. 2024

Pneumon

Self Cite

View full text Add to dashboard Cite

show abstract

“…Price, unpublished data). These biomarkers identify impaired vascular barrier function and limited vascular repair as potential maladaptive leukocyte-independent mechanisms of vascular injury in neutropenic ARDS, resulting in worse outcomes (134). Vascular therapies that address hyperinflammation/hyperpermeability from exaggerated barrier disruptors or loss of platelet trophogens could be particularly beneficial in high vascular injury ARDS subjects typified by neutrophil-and platelet-depleted ARDS subjects (Figure 4).…”

Section: Identifying High Vascular Injury Acute Respiratory Distress ...mentioning

confidence: 99%

A Razor's Edge: Vascular Responses to Acute Inflammatory Lung Injury/Acute Respiratory Distress Syndrome

Price,

Garcia

2024

Annu. Rev. Physiol.

Self Cite

View full text Add to dashboard Cite

Historically considered a metabolically inert cellular layer separating the blood from the underlying tissue, the endothelium is now recognized as a highly dynamic, metabolically active tissue that is critical to organ homeostasis. Under homeostatic conditions, lung endothelial cells (ECs) in healthy subjects are quiescent, promoting vasodilation, platelet disaggregation, and anti-inflammatory mechanisms. In contrast, lung ECs are essential contributors to the pathobiology of acute respiratory distress syndrome (ARDS), as the quiescent endothelium is rapidly and radically altered upon exposure to environmental stressors, infectious pathogens, or endogenous danger signals into an effective and formidable regulator of innate and adaptive immunity. These dramatic perturbations, produced in a tsunami of inflammatory cascade activation, result in paracellular gap formation between lung ECs, sustained lung edema, and multi-organ dysfunction that drives ARDS mortality. The astonishing plasticity of the lung endothelium in negotiating this inflammatory environment and efforts to therapeutically target the aberrant ARDS endothelium are examined in further detail in this review.

show abstract

“…All included subjects were endotracheally intubated and had ARDS. As previously (18)(19)(20), we were granted access to data after submitting a prospective protocol to the Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) of the National Heart, Lung, and Blood Institute (NHLBI). Because the data would be received in deidentified form (nonhuman subjects research), the institutional review board of Evangelismos Hospital waived the need of informed consent and approved the study (protocol number 140/5-5-2022).…”

Section: Study Design and Patient Populationmentioning

confidence: 99%

Prolonged Mechanical Ventilation in Acute Respiratory Distress Syndrome

Andrianopoulos,

Giannakoulis,

Papoutsi

et al. 2023

Shock

Self Cite

View full text Add to dashboard Cite

Purpose Trajectory of acute respiratory distress syndrome (ARDS) spans from rapidly improving cases to cases receiving prolonged mechanical ventilation (PMV). We attempted to estimate temporal trends of prevalence and mortality of PMV and to identify risk factors associated with mortality of patients with ARDS receiving PMV. Methods We performed a secondary analysis of individual patient data from six randomized controlled clinical trials conducted by the ARDS Network. PMV was defined as the need for mechanical ventilation for >21 consecutive days. Results Of 4216 patients with ARDS, 646 (15.3%) received PMV. Prevalence of PMV gradually declined from 18.4% in the ARMA (published in 2000) trial to 10.9% in the SAILS (2014) trial (R2 = 0.728, p = 0.031). 90-day mortality of patients receiving PMV did not change over time (R2 = 0.271, p = 0.290) and remained as high as 36.8%. Ιn the three most recent trials, risk factors associated with mortality among the 250 patients with ARDS receiving PMV included age, malignancy, pneumonia as the cause of ARDS, coagulation dysfunction and hepatic dysfunction during the first 21 days after trial enrollment. Conclusion Although prevalence of PMV among patients enrolled in ARDS Network trials gradually declined, mortality did not change. Risk factors associated with mortality were mostly non-modifiable.

show abstract

Temporal trends of outcomes of neutropenic patients with ARDS enrolled in therapeutic clinical trials

Cited by 8 publications

References 5 publications

Drug-overdose associated acute hypoxemic respiratory failure: A secondary analysis

Drug-overdose associated acute hypoxemic respiratory failure: A secondary analysis

A Razor's Edge: Vascular Responses to Acute Inflammatory Lung Injury/Acute Respiratory Distress Syndrome

Prolonged Mechanical Ventilation in Acute Respiratory Distress Syndrome

Contact Info

Product

Resources

About